Why might a 64-year-old man on apixaban (Eliquis) have an elevated platelet count (thrombocytosis)?

Apixaban Does Not Cause Thrombocytosis

Apixaban (Eliquis) does not increase platelet counts—it is an anticoagulant that inhibits clot formation without affecting platelet production or numbers. If a patient on apixaban has elevated platelets, this represents a separate underlying condition that requires independent evaluation.

Why Apixaban Cannot Cause Thrombocytosis

Apixaban is a direct factor Xa inhibitor that prevents thrombin generation and fibrin formation 1. Its mechanism of action involves:

• Selective inhibition of factor Xa, blocking the conversion of prothrombin to thrombin 2
• No effect on platelet production in the bone marrow 1
• No stimulation of thrombopoietin or other platelet growth factors 2

Studies specifically examining apixaban's effect on platelet function demonstrate that it does not alter platelet reactivity, activation markers (P-selectin, thrombospondin), or platelet counts 3.

Actual Causes of Thrombocytosis in This Patient

When a 64-year-old man on apixaban presents with elevated platelets, investigate these etiologies:

Primary (Clonal) Thrombocytosis

• Essential thrombocythemia (ET): A myeloproliferative neoplasm requiring JAK2, CALR, or MPL mutation testing 4, 5
• Polycythemia vera (PV): Check hematocrit, JAK2 mutation status 6, 7
• Other myeloproliferative disorders: Consider chronic myeloid leukemia, primary myelofibrosis 4

Key distinction: Clonal thrombocytosis carries significantly higher thrombotic risk than reactive causes, with thrombosis rates of 10-25% even with platelet counts >1,000 × 10⁹/L 4, 8. This explains why this patient may be on apixaban—the anticoagulation is treating the thrombotic risk from the underlying myeloproliferative disorder, not causing the elevated platelets 6, 5.

Secondary (Reactive) Thrombocytosis

• Infection or inflammation: Acute phase reaction 9
• Iron deficiency: Causes transient thrombocytosis 9
• Malignancy: Solid tumors, lymphoma 6
• Post-surgical state: Especially after splenectomy 7
• Tissue damage: Trauma, burns 8

Clinical Approach to This Patient

Immediate Assessment

1. Review complete blood count trends: Determine if thrombocytosis is new or chronic 4
2. Examine other cell lines: Leukocytosis and elevated hematocrit suggest PV; isolated thrombocytosis suggests ET 4, 7
3. Assess thrombotic history: Prior thrombosis is the strongest risk factor for recurrence in myeloproliferative disorders 4

Diagnostic Workup

• JAK2 V617F mutation testing: Present in 50-60% of ET cases 4, 5
• CALR and MPL mutations: If JAK2 negative, these account for most remaining ET cases 5
• Bone marrow biopsy: May be needed if mutations are negative but clinical suspicion remains high 4
• Inflammatory markers: CRP, ESR to evaluate for reactive causes 8
• Iron studies: Ferritin, TIBC, serum iron 9

Risk Stratification for Myeloproliferative Disorders

High-risk criteria requiring cytoreductive therapy 4:

• Age >60 years (this patient is 64)
• Prior thrombosis history
• JAK2 mutation positive
• Leukocytosis at diagnosis

Low-risk criteria 4:

• Age ≤60 years
• No prior thrombosis
• No JAK2 mutation

Management Implications

If Essential Thrombocythemia is Diagnosed

High-risk patients (age >60 or prior thrombosis) 4:

• Continue anticoagulation with apixaban for thrombosis prevention 6, 5
• Add cytoreductive therapy: hydroxyurea (500 mg twice daily initially) 4, 7
• Target platelet count <400 × 10⁹/L 4
• Consider aspirin 81-100 mg daily for microvascular symptoms 4

Low-risk patients 4:

• Observation with cardiovascular risk factor management
• Aspirin for vasomotor symptoms
• Reserve cytoreductive therapy for symptomatic thrombocytosis or progressive disease

If Reactive Thrombocytosis is Identified

• Treat underlying cause (infection, inflammation, iron deficiency) 8, 9
• Reactive thrombocytosis rarely requires specific platelet-lowering therapy 8
• Continue apixaban if original indication (atrial fibrillation, prior VTE) remains valid 1

Critical Pitfall to Avoid

Do not attribute thrombocytosis to apixaban and discontinue anticoagulation. This patient likely has apixaban prescribed because of thrombotic risk from an underlying myeloproliferative disorder 6, 5. Stopping anticoagulation could precipitate life-threatening thrombosis, including Budd-Chiari syndrome, splanchnic vein thrombosis, or stroke 5, 10.

The thrombocytosis and the apixaban prescription are both consequences of the same underlying pathology—not a cause-and-effect relationship 4, 5.